FDA advisory panel recommends approval of TB Alliance's tuberculosis treatment
Independent experts of an FDA advisory panel voted in favor of the not-for-profit TB Alliances treatment for drug resistant tuberculosis, as a part of a three-drug combination regimen.The panel on Tuesday voted 14-4 when asked to assess the treatment, pretomanid, in combination with Johnson & Johnsons bedaquiline and linezolid for multi-drug resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). (ET Healthworld, June 7, 2019)
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies